Aceclofenac 100mg tablets
Prescription only
Requires a prescription from a doctor or prescriber
Tablet
100mg
Oral
Aceclofenac is an oral non-steroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and analgesic properties used to treat osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
Active ingredients:
Aceclofenac
No active safety alerts
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Source: MHRA Products DatabaseOGL 3.0
Updated 3 months ago(16 Jan 2026)Safety monitoring data
Yellow Card reports
MHRA
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Aceclofenac
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
EMA
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Aceclofenac
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
20 branded products available
Show details
20 products
MHRA licensed products
View all licensed products for Aceclofenac on the MHRA register
Preservex 100mg tablets
Preservex 100mg tablets
Aceclofenac 100mg tablets
Aceclofenac 100mg tablets
Aceclofenac 100mg tablets
Aceclofenac 100mg tablets
Aceclofenac 100mg tablets
Aceclofenac 100mg tablets
Aceclofenac 100mg tablets
Aceclofenac 100mg tablets
Show details
£8.67indicative price
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
200 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Show details
Diclofenac 75mg/1ml solution for injection ampoules
Injection
75mg/1ml
Same therapeutic group
Tolmetin 600mg tablets
Tablet
600mg
Same therapeutic group
Diclofenac 40mg/5ml oral solution
Oral solution
40mg/5ml
Same therapeutic group
Diclofenac 40mg/5ml oral suspension
Oral suspension
40mg/5ml
Same therapeutic group
Diclofenac 10mg dispersible tablets
Tablet
10mg
Same therapeutic group
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Show details
Loading prescribing data...
Clinical guidelines and formulary information
British National Formulary
Aceclofenac
BNF
Drug monograph — bnf.nice.org.ukSource: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Show details
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
Show details
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Show details
Searching UK clinical trials...
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
160 found
Half-life
4 hours
Mechanism
Through COX-2 inhibition, aceclofenac downregulates the production of various in…
Food interactions
1 warning
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
1.25 to 3 hours
Aceclofenac is rapidly and completely absorbed from the gastrointestinal tract and circulates mainly as unchanged drug following oral administration.…
Half-life
4 hours
The mean plasma elimination half-life is approximately 4 hours .
[L868]
[L868]
Protein binding
99%
It is reported to be highly protein-bound (>99%) .
[L868]
[L868]
Volume of distribution
25 L
The volume of distribution is approximately 25 L .
[L868]
[L868]
Metabolism
4'-hydroxyaceclofenac is the main metabolite detected in plasma however other minor metabolites include diclofenac, 5-hydroxyaceclofenac, 5-hydroxydiclofenac, and 4'-hydroxydiclofenac .
[A19667]…
[A19667]…
Elimination
70-80%
The main route of elimination is via the urine where the elimination accounts for 70-80% of clearance of the drug .
[A19667]…
[A19667]…
Clearance
5 L/h
The mean clearance rate is approximately 5 L/h .
[A19674]
[A19674]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Status:
Approved
Small molecule
About this compound
Aceclofenac is an oral non-steroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and analgesic properties used to treat osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. It is reported to have a higher anti-inflammatory action or at least comparable effects than conventional NSAIDs in double-blind studies [A19667][A19668][A19670]. Aceclofenac potently inhibits the cyclo-oxygenase enzyme (COX) that is involved in the synthesis of prostaglandins, which are inflammatory mediators that cause pain, swelling, inflammation, and fever. Aceclofenac belongs to BCS Class II as it possesses poor aqueous solubility [A19667]. It displays high permeability to penetrate into synovial joints where in patients with osteoarthritis and related conditions, the loss of articular cartilage in the area causes joint pain, tenderness, stiffness, crepitus, and local inflammation [A19666]. Aceclofenac is also reported to be effective in other painful conditions such as dental and gynaecological conditions [A19672]. In 1991, aceclofenac was developed as an analog of a commonly prescribed NSAID, DB00586, via chemical modification in effort to improve the gastrointestinal tolerability of the drug. It is a more commonly prescribed drug in Europe.
Properties:
solid
Avg. mass: 354.18 Da
DrugBank indication
Aceclofenac is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
Also known as(39)
2-[(2,6-dichlorophenyl)amino]benzeneacetic acid carboxymethyl ester
2-[(2,6-dichlorophenyl)amino]phenylacetoxyacetic acid
2-[(2',6'-dichlorophenyl)amino]phenylacetoxyacetic acid
Aceclofenac
Acéclofénac
Aceclofenac betadex
Aceclofenaco
Aceclofenacum
Dosage forms(20)
Tablet (Oral) — 100 mg
Tablet, film coated (Oral) — 100 mg
Injection, powder, lyophilized, for solution (Parenteral) — 0.15 g
Tablet, film coated (Oral) — 0.1 g
Tablet, film coated (Oral) — 100 mg/1
Powder (Oral) — 100.000 mg
Tablet (Oral) — 100.00 mg
Cream (Topical) — 1.5 g
Molecular properties(19)
Drug interactions(1433)
Known interactions with other medications. Always consult a healthcare professional.
Amlodipine
Moderate
Aceclofenac may decrease the antihypertensive activities of Amlodipine.
Phentermine
Unknown severity
The risk or severity of hypertension can be increased when Phentermine is combined with Aceclofenac.
The risk or severity of hypertension can be increased when Midodrine is combined with Aceclofenac.
Isoetharine
Unknown severity
The risk or severity of hypertension can be increased when Isoetharine is combined with Aceclofenac.
Ziprasidone
Unknown severity
The risk or severity of hypertension can be increased when Ziprasidone is combined with Aceclofenac.
Methysergide
Unknown severity
The risk or severity of hypertension can be increased when Methysergide is combined with Aceclofenac.
Cabergoline
Unknown severity
The risk or severity of hypertension can be increased when Cabergoline is combined with Aceclofenac.
Zolmitriptan
Unknown severity
The risk or severity of hypertension can be increased when Zolmitriptan is combined with Aceclofenac.
Dihydroergotamine
Unknown severity
The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Aceclofenac.
Methylergometrine
Unknown severity
The risk or severity of hypertension can be increased when Methylergometrine is combined with Aceclofenac.
Norepinephrine
Unknown severity
The risk or severity of hypertension can be increased when Norepinephrine is combined with Aceclofenac.
Mirtazapine
Unknown severity
The risk or severity of hypertension can be increased when Mirtazapine is combined with Aceclofenac.
Phenylephrine
Unknown severity
The risk or severity of hypertension can be increased when Phenylephrine is combined with Aceclofenac.
Phenylpropanolamine
Unknown severity
The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Aceclofenac.
Droperidol
Unknown severity
The risk or severity of hypertension can be increased when Droperidol is combined with Aceclofenac.
The risk or severity of hypertension can be increased when Doxapram is combined with Aceclofenac.
The risk or severity of hypertension can be increased when Atropine is combined with Aceclofenac.
The risk or severity of hypertension can be increased when Lisuride is combined with Aceclofenac.
The risk or severity of hypertension can be increased when Linezolid is combined with Aceclofenac.
Metaraminol
Unknown severity
The risk or severity of hypertension can be increased when Metaraminol is combined with Aceclofenac.
Furazolidone
Unknown severity
The risk or severity of hypertension can be increased when Furazolidone is combined with Aceclofenac.
Thioridazine
Unknown severity
The risk or severity of hypertension can be increased when Thioridazine is combined with Aceclofenac.
Ergotamine
Unknown severity
The risk or severity of hypertension can be increased when Ergotamine is combined with Aceclofenac.
Nicergoline
Unknown severity
The risk or severity of hypertension can be increased when Nicergoline is combined with Aceclofenac.
Sufentanil
Unknown severity
The risk or severity of hypertension can be increased when Sufentanil is combined with Aceclofenac.
Methoxamine
Unknown severity
The risk or severity of hypertension can be increased when Methoxamine is combined with Aceclofenac.
Risperidone
Unknown severity
The risk or severity of hypertension can be increased when Risperidone is combined with Aceclofenac.
Isoflurane
Unknown severity
The risk or severity of hypertension can be increased when Isoflurane is combined with Aceclofenac.
Propiomazine
Unknown severity
The risk or severity of hypertension can be increased when Propiomazine is combined with Aceclofenac.
Alfentanil
Unknown severity
The risk or severity of hypertension can be increased when Alfentanil is combined with Aceclofenac.
The risk or severity of hypertension can be increased when Minaprine is combined with Aceclofenac.
Orciprenaline
Unknown severity
The risk or severity of hypertension can be increased when Orciprenaline is combined with Aceclofenac.
Phenmetrazine
Unknown severity
The risk or severity of hypertension can be increased when Phenmetrazine is combined with Aceclofenac.
Trifluoperazine
Unknown severity
The risk or severity of hypertension can be increased when Trifluoperazine is combined with Aceclofenac.
Pseudoephedrine
Unknown severity
The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Aceclofenac.
Benzphetamine
Unknown severity
The risk or severity of hypertension can be increased when Benzphetamine is combined with Aceclofenac.
The risk or severity of hypertension can be increased when Ritodrine is combined with Aceclofenac.
Flupentixol
Unknown severity
The risk or severity of hypertension can be increased when Flupentixol is combined with Aceclofenac.
Remifentanil
Unknown severity
The risk or severity of hypertension can be increased when Remifentanil is combined with Aceclofenac.
Bitolterol
Unknown severity
The risk or severity of hypertension can be increased when Bitolterol is combined with Aceclofenac.
Oxymetazoline
Unknown severity
The risk or severity of hypertension can be increased when Oxymetazoline is combined with Aceclofenac.
Diethylpropion
Unknown severity
The risk or severity of hypertension can be increased when Diethylpropion is combined with Aceclofenac.
Salmeterol
Unknown severity
The risk or severity of hypertension can be increased when Salmeterol is combined with Aceclofenac.
Naratriptan
Unknown severity
The risk or severity of hypertension can be increased when Naratriptan is combined with Aceclofenac.
Frovatriptan
Unknown severity
The risk or severity of hypertension can be increased when Frovatriptan is combined with Aceclofenac.
Ergoloid mesylate
Unknown severity
The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Aceclofenac.
Isoprenaline
Unknown severity
The risk or severity of hypertension can be increased when Isoprenaline is combined with Aceclofenac.
Arbutamine
Unknown severity
The risk or severity of hypertension can be increased when Arbutamine is combined with Aceclofenac.
Dutasteride
Unknown severity
The risk or severity of hypertension can be increased when Dutasteride is combined with Aceclofenac.
The risk or severity of hypertension can be increased when Pergolide is combined with Aceclofenac.
Showing 50 of 1433 interactions
Food & lifestyle interactions
Advice
Take with or without food.
Toxicity & overdose
Some common adverse effects include gastro-intestinal disorders (dyspepsia, abdominal pain, nausea), rash, ruber, urticaria, symptoms of enuresis, headache, dizziness, and drowsiness .
[L869]
Oral LD50 value in rats is 130 mg/kg MSDS.
[L869]
Oral LD50 value in rats is 130 mg/kg MSDS.
How it works
Mechanism of action
Through COX-2 inhibition, aceclofenac downregulates the production of various inflammatory mediators including prostaglandin E2 (PGE2), IL-1β, and TNF from the arachidonic acid (AA) pathway. Inhibition of IL-6 is thought to be mediated by diclofenac converted from aceclofenac [A19671]. Suppressed action of inflammatory cytokines decreases the production of reactive oxygen species. Aceclofenac is shown to decreased production of nitrous oxide in human articular chondrocytes [A19667]. In addition, aceclofenac interferes with neutrophil adhesion to endothelium by decreasing the expression of L-selectin (CD62L), which is a cell adhesion molecule expressed on lymphocytes [A19673]. Aceclofenac is proposed to stimulate the synthesis of glycosaminoglycan in human osteoarthritic cartilage which may be mediated through its inhibitory action on IL-1 production and activity [A19666]. The chrondroprotective effects are generated by 4'-hydroxyaceclofenac which suppresses IL-1 mediated production of promatrix metalloproteinase-1 and metalloproteinase-3 and interferes with the release of proteoglycan from chrondrocytes [A19666][A19667][A19672].
Pharmacodynamics
Aceclofenac is a NSAID that inhibits both isoforms of COX enzyme, a key enzyme involved in the inflammatory cascade. COX-1 enzyme is a constitutive enzyme involved in prostacyclin production and protective functions of gastric mucosa whereas COX-2 is an inducible enzyme involved in the production of inflammatory mediators in response to inflammatory stimuli. Aceclofenac displays more selectivity towards COX-2 (IC50 of 0.77uM) than COX-1 (IC50 of >100uM), which promotes its gastric tolerance compared to other NSAIDs. The primary metabolite, 4'-hydroxyaceclofenac, also minimally inhibits COX-2 with IC50 value of 36uM [A19667]. Although the mode of action of aceclofenac is thought to mainly arise from the inhibition of synthesis of prostaglandins (PGE2), aceclofenac also inhibits the production of inflammatory cytokines, interleukins (IL-1β, IL-6), and tumor necrosis factors (TNF) [A19666][A19667]. It is also reported that aceclofenac also affects the cell adhesion molecules from neutrophils [A19673]. Aceclofenac also targets the synthesis of glycosaminoglycan and mediates chrondroprotective effects [A19666].
Pharmacokinetics
How the body processes this drug — absorption, distribution, metabolism, and elimination
Absorption
Aceclofenac is rapidly and completely absorbed from the gastrointestinal tract and circulates mainly as unchanged drug following oral administration. Peak plasma concentrations are reached around 1.25 to 3 hours post-ingestion, and the drug penetrates into the synovial fluid where the concentration may reach up to 60% of that in the plasma .
[L868]
There is no accumulation in regular dosing, with similar maximum plasma concentration (Cmax) and time to reach peak plasma concentration (Tmax) after single and multiple doses .
[A19667]
[L868]
There is no accumulation in regular dosing, with similar maximum plasma concentration (Cmax) and time to reach peak plasma concentration (Tmax) after single and multiple doses .
[A19667]
Half-life
The mean plasma elimination half-life is approximately 4 hours .
[L868]
[L868]
Protein binding
It is reported to be highly protein-bound (>99%) .
[L868]
[L868]
Volume of distribution
The volume of distribution is approximately 25 L .
[L868]
[L868]
Metabolism
4'-hydroxyaceclofenac is the main metabolite detected in plasma however other minor metabolites include diclofenac, 5-hydroxyaceclofenac, 5-hydroxydiclofenac, and 4'-hydroxydiclofenac .
[A19667]
It is probable that the metabolism of aceclofenac is mediated by CYP2C9 .
[A19674]
[A19667]
It is probable that the metabolism of aceclofenac is mediated by CYP2C9 .
[A19674]
Route of elimination
The main route of elimination is via the urine where the elimination accounts for 70-80% of clearance of the drug .
[A19667]
Approximately two thirds of the administered dose is excreted via the urine, mainly as glucuronidated and hydroxylated forms of aceclofenac .
[L868]
About 20% of the dose is excreted into feces .
[A19671]
[A19667]
Approximately two thirds of the administered dose is excreted via the urine, mainly as glucuronidated and hydroxylated forms of aceclofenac .
[L868]
About 20% of the dose is excreted into feces .
[A19671]
Clearance
The mean clearance rate is approximately 5 L/h .
[A19674]
[A19674]
Drug targets(2)
Proteins and enzymes this drug interacts with in the body
Prostaglandin G/H synthase 2
PTGS2
inhibitor
Specific functionenzyme binding
Cellular location
Microsome membrane
General function & pharmacology
Dual cyclooxygenase and peroxidase in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory response .
PMID:11939906 PMID:16373578 PMID:19540099 PMID:22942274 PMID:26859324 PMID:27226593 PMID:7592599 PMID:7947975 PMID:9261177
The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series prostaglandins and thromboxanes .
PMID:16373578 PMID:22942274 PMID:26859324 PMID:27226593 PMID:7592599 PMID:7947975 PMID:9261177
This complex transformation is initiated by abstraction of hydrogen at carbon 13 (with S-stereochemistry), followed by insertion of molecular O2 to form the endoperoxide bridge between carbon 9 and 11 that defines prostaglandins. The insertion of a second molecule of O2 (bis-oxygenase activity) yields a hydroperoxy group in PGG2 that is then reduced to PGH2 by two electrons .
PMID:16373578 PMID:22942274 PMID:26859324 PMID:27226593 PMID:7592599 PMID:7947975 PMID:9261177
Similarly catalyzes successive cyclooxygenation and peroxidation of dihomo-gamma-linoleate (DGLA, C20:3(n-6)) and eicosapentaenoate (EPA, C20:5(n-3)) to corresponding PGH1 and PGH3, the precursors of 1- and 3-series prostaglandins .
PMID:11939906 PMID:19540099
In an alternative pathway of prostanoid biosynthesis, converts 2-arachidonoyl lysophopholipids to prostanoid lysophopholipids, which are then hydrolyzed by intracellular phospholipases to release free prostanoids .
PMID:27642067
Metabolizes 2-arachidonoyl glycerol yielding the glyceryl ester of PGH2, a process that can contribute to pain response .
PMID:22942274
Generates lipid mediators from n-3 and n-6 polyunsaturated fatty acids (PUFAs) via a lipoxygenase-type mechanism. Oxygenates PUFAs to hydroperoxy compounds and then reduces them to corresponding alcohols .
PMID:11034610 PMID:11192938 PMID:9048568 PMID:9261177
Plays a role in the generation of resolution phase interaction products (resolvins) during both sterile and infectious inflammation .
PMID:12391014
Metabolizes docosahexaenoate (DHA, C22:6(n-3)) to 17R-HDHA, a precursor of the D-series resolvins (RvDs) .
PMID:12391014
As a component of the biosynthetic pathway of E-series resolvins (RvEs), converts eicosapentaenoate (EPA, C20:5(n-3)) primarily to 18S-HEPE that is further metabolized by ALOX5 and LTA4H to generate 18S-RvE1 and 18S-RvE2 .
PMID:21206090
In vascular endothelial cells, converts docosapentaenoate (DPA, C22:5(n-3)) to 13R-HDPA, a precursor for 13-series resolvins (RvTs) shown to activate macrophage phagocytosis during bacterial infection .
PMID:26236990
In activated leukocytes, contributes to oxygenation of hydroxyeicosatetraenoates (HETE) to diHETES (5,15-diHETE and 5,11-diHETE) .
PMID:22068350 PMID:26282205
Can also use linoleate (LA, (9Z,12Z)-octadecadienoate, C18:2(n-6)) as substrate and produce hydroxyoctadecadienoates (HODEs) in a regio- and stereospecific manner, being (9R)-HODE ((9R)-hydroxy-(10E,12Z)-octadecadienoate) and (13S)-HODE ((13S)-hydroxy-(9Z,11E)-octadecadienoate) its major products (By similarity).
During neuroinflammation, plays a role in neuronal secretion of specialized preresolving mediators (SPMs) 15R-lipoxin A4 that regulates phagocytic microglia (By similarity)
PMID:11939906 PMID:16373578 PMID:19540099 PMID:22942274 PMID:26859324 PMID:27226593 PMID:7592599 PMID:7947975 PMID:9261177
The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series prostaglandins and thromboxanes .
PMID:16373578 PMID:22942274 PMID:26859324 PMID:27226593 PMID:7592599 PMID:7947975 PMID:9261177
This complex transformation is initiated by abstraction of hydrogen at carbon 13 (with S-stereochemistry), followed by insertion of molecular O2 to form the endoperoxide bridge between carbon 9 and 11 that defines prostaglandins. The insertion of a second molecule of O2 (bis-oxygenase activity) yields a hydroperoxy group in PGG2 that is then reduced to PGH2 by two electrons .
PMID:16373578 PMID:22942274 PMID:26859324 PMID:27226593 PMID:7592599 PMID:7947975 PMID:9261177
Similarly catalyzes successive cyclooxygenation and peroxidation of dihomo-gamma-linoleate (DGLA, C20:3(n-6)) and eicosapentaenoate (EPA, C20:5(n-3)) to corresponding PGH1 and PGH3, the precursors of 1- and 3-series prostaglandins .
PMID:11939906 PMID:19540099
In an alternative pathway of prostanoid biosynthesis, converts 2-arachidonoyl lysophopholipids to prostanoid lysophopholipids, which are then hydrolyzed by intracellular phospholipases to release free prostanoids .
PMID:27642067
Metabolizes 2-arachidonoyl glycerol yielding the glyceryl ester of PGH2, a process that can contribute to pain response .
PMID:22942274
Generates lipid mediators from n-3 and n-6 polyunsaturated fatty acids (PUFAs) via a lipoxygenase-type mechanism. Oxygenates PUFAs to hydroperoxy compounds and then reduces them to corresponding alcohols .
PMID:11034610 PMID:11192938 PMID:9048568 PMID:9261177
Plays a role in the generation of resolution phase interaction products (resolvins) during both sterile and infectious inflammation .
PMID:12391014
Metabolizes docosahexaenoate (DHA, C22:6(n-3)) to 17R-HDHA, a precursor of the D-series resolvins (RvDs) .
PMID:12391014
As a component of the biosynthetic pathway of E-series resolvins (RvEs), converts eicosapentaenoate (EPA, C20:5(n-3)) primarily to 18S-HEPE that is further metabolized by ALOX5 and LTA4H to generate 18S-RvE1 and 18S-RvE2 .
PMID:21206090
In vascular endothelial cells, converts docosapentaenoate (DPA, C22:5(n-3)) to 13R-HDPA, a precursor for 13-series resolvins (RvTs) shown to activate macrophage phagocytosis during bacterial infection .
PMID:26236990
In activated leukocytes, contributes to oxygenation of hydroxyeicosatetraenoates (HETE) to diHETES (5,15-diHETE and 5,11-diHETE) .
PMID:22068350 PMID:26282205
Can also use linoleate (LA, (9Z,12Z)-octadecadienoate, C18:2(n-6)) as substrate and produce hydroxyoctadecadienoates (HODEs) in a regio- and stereospecific manner, being (9R)-HODE ((9R)-hydroxy-(10E,12Z)-octadecadienoate) and (13S)-HODE ((13S)-hydroxy-(9Z,11E)-octadecadienoate) its major products (By similarity).
During neuroinflammation, plays a role in neuronal secretion of specialized preresolving mediators (SPMs) 15R-lipoxin A4 that regulates phagocytic microglia (By similarity)
Prostaglandin G/H synthase 1
PTGS1
inhibitor
Specific functionheme binding
Cellular location
Microsome membrane
General function & pharmacology
Dual cyclooxygenase and peroxidase that plays an important role in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory response. The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series prostaglandins and thromboxanes. This complex transformation is initiated by abstraction of hydrogen at carbon 13 (with S-stereochemistry), followed by insertion of molecular O2 to form the endoperoxide bridge between carbon 9 and 11 that defines prostaglandins.
The insertion of a second molecule of O2 (bis-oxygenase activity) yields a hydroperoxy group in PGG2 that is then reduced to PGH2 by two electrons .
PMID:7947975
Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the generation of thromboxane A2 (TXA2), which promotes platelet activation and aggregation, vasoconstriction and proliferation of vascular smooth muscle cells (Probable).
Can also use linoleate (LA, (9Z,12Z)-octadecadienoate, C18:2(n-6)) as substrate and produce hydroxyoctadecadienoates (HODEs) in a regio- and stereospecific manner, being (9R)-HODE ((9R)-hydroxy-(10E,12Z)-octadecadienoate) and (13S)-HODE ((13S)-hydroxy-(9Z,11E)-octadecadienoate) its major products (By similarity)
The insertion of a second molecule of O2 (bis-oxygenase activity) yields a hydroperoxy group in PGG2 that is then reduced to PGH2 by two electrons .
PMID:7947975
Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the generation of thromboxane A2 (TXA2), which promotes platelet activation and aggregation, vasoconstriction and proliferation of vascular smooth muscle cells (Probable).
Can also use linoleate (LA, (9Z,12Z)-octadecadienoate, C18:2(n-6)) as substrate and produce hydroxyoctadecadienoates (HODEs) in a regio- and stereospecific manner, being (9R)-HODE ((9R)-hydroxy-(10E,12Z)-octadecadienoate) and (13S)-HODE ((13S)-hydroxy-(9Z,11E)-octadecadienoate) its major products (By similarity)
Metabolizing enzymes(1)
Enzymes involved in drug metabolism — important for understanding drug interactions
Enzyme activity key
substrate
inhibitor
inducer
CYP2C9Cytochrome P450 2C9
substrate
Scientific references(10)
Raza K., Kumar M., Kumar P., Malik R., Sharma G., Kaur M., Katare O.P.
Topical delivery of aceclofenac: challenges and promises of novel drug delivery systems.
Biomed Research International
20142014:406731. doi: 10.1155/2014/406731. Epub 2014 Jun 18
Legrand E.
Aceclofenac in the management of inflammatory pain.
Expert Opinion on Pharmacotherapy
20045(6):1347-1357. doi: 10.1517/14656566.5.6.1347
Pareek A., Chandurkar N.
Comparison of gastrointestinal safety and tolerability of aceclofenac with diclofenac: a multicenter, randomized, double-blind study in patients with knee osteoarthritis.
Curr Medicine Research Opinion
2013 Jul29(7):849-59. doi: 10.1185/03007995.2013.795139. Epub 2013 Apr 30
Moore R.A., Derry S., McQuay H.J.
Single dose oral aceclofenac for postoperative pain in adults.
Cochrane Database of Systematic Reviews
2009 Jul 8(3):CD007588. doi: 10.1002/14651858.CD007588.pub2
Pareek A., Chandurkar N., Gupta A., Sirsikar A., Dalal B., Jesalpura B., Mehrotra A., Mukherjee A.
Efficacy and safety of aceclofenac-cr and aceclofenac in the treatment of knee osteoarthritis: a 6-week, comparative, randomized, multicentric, double-blind study.
Journal Pain
2011 May12(5):546-53. doi: 10.1016/j.jpain.2010.10.013. Epub 2011 Feb 1
Brogden R.N., Wiseman L.R.
Aceclofenac.
A review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management
Drugs. 1996 Jul52(1):113-24. doi: 10.2165/00003495-199652010-00008
Dooley M., Spencer C.M., Dunn C.J.
Aceclofenac.
Drugs
200161(9):1351-1378. doi: 10.2165/00003495-200161090-00012
Gonzalez-Alvaro I., Carmona L., Diaz-Gonzalez F., Gonzalez-Amaro R., Mollinedo F., Sanchez-Madrid F., Laffon A., Garcia-Vicuna R.
CD69 expression on lymphocytes and interleukin-15 levels in synovial fluids from different inflammatory arthropathies.
Rheumatology International
200221(5):182-188. doi: 10.1007/s00296-001-0161-z
Ghosh S., Barik B.B.
A Comparative Study of the Pharmacokinetics of Conventional and Sustained-release Tablet Formulations of Aceclofenac in Healthy Male Subjects.
Tropical Journal of Pharmaceutical Research
20109(4). doi: 10.4314/tjpr.v9i4.58939
Dahiya S., Kaushik A., Pathak K.
Improved Pharmacokinetics of Aceclofenac Immediate Release Tablets Incorporating its Inclusion Complex with Hydroxypropyl-beta-Cyclodextrin.
Science Pharmacy
2015 Feb 283(3):501-10. doi: 10.3797/scipharm.1509-07. Print 2015 Jul-Sep
ATC classification(2 codes)
ATC M01AB16
ATC M02AA25
International brands(3)
Experimental properties(3)
Commercial products(1)
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Aceclofenac
Additional database identifiers
ChemSpider
64809
BindingDB
50109016
ZINC
ZINC000003805798
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9605
GenAtlas
PTGS2
GeneCards
PTGS2
GenBank Gene Database
L15326
GenBank Protein Database
291988
Guide to Pharmacology
1376
UniProt Accession
PGH2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9604
GenAtlas
PTGS1
GeneCards
PTGS1
GenBank Gene Database
M31822
GenBank Protein Database
387018
Guide to Pharmacology
1375
UniProt Accession
PGH1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2623
GenAtlas
CYP2C9
GeneCards
CYP2C9
GenBank Gene Database
AY341248
Guide to Pharmacology
1326
UniProt Accession
CP2C9_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Knox C., Wilson M., Klinger C.M., et al
DrugBank 6.
0: the DrugBank Knowledgebase for 2024
Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
Wishart D.S., Feunang Y.D., Guo A.C., et al
DrugBank 5.
0: a major update to the DrugBank database for 2018
Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
Show earlier publications
Law V., Knox C., Djoumbou Y., et al
DrugBank 4.
0: shedding new light on drug metabolism
Nucleic Acids Res. 2014 Jan 142(1):D1091-7
Knox C., Law V., Jewison T., et al
DrugBank 3.
0: a comprehensive resource for 'omics' research on drugs
Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Research
2008 Jan36(Database issue):D901-6
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a comprehensive resource for in silico drug discovery and exploration.
Nucleic Acids Research
2006 Jan 134(Database issue):D668-72
Source: go.drugbank.comCC BY-NC 4.0
Updated 27 days ago(8 Mar 2026)